Anti Microbial Segment

Reso-Penem™ Injection 300mg

Next-Gen Carbapenem — Rest Assured against resistant pathogens.

Reso-Penem™ Injection 300mg

Chemical Composition

Each vial contains Biapenem 300mg (For IV Infusion Only). Supplied with 10 ML Sterile Water for Injection.

Indications

Complicated Urinary Tract Infections (Resistant Organism, Pyelonephritis), Intra-Abdominal Infections (Peritonitis, Abdominal Abscesses), Lower RTI (Hospital-Acquired & Broncho Pneumonia), Septicemia, Skin & Soft Tissue Infections, Gynecological Infections (PID & Endometriosis), Severe Systemic Hospitalised Infections

Disclaimer: Information on this page is intended for healthcare practitioners and is not a substitute for professional medical advice. Please consult your physician before using any product.

Biapenem injection 300mg — about Reso-Penem

Reso-Penem is a biapenem injection manufactured by Resarcio India LLP. Each vial delivers Biapenem 300mg for intravenous infusion only and is supplied with 10 ml sterile water for injection, making it a convenient, ready-to-reconstitute carbapenem for hospital use.

Why clinicians choose biapenem

Biapenem is a next-generation carbapenem with broad-spectrum activity against Gram-positive, Gram-negative and anaerobic pathogens, including many ESBL-producing and multidrug-resistant organisms. It offers high stability to renal dehydropeptidase-1, so no cilastatin is required, and is associated with a favourable central nervous system tolerability profile compared with older carbapenems.

Choosing the best biapenem injection

When selecting a biapenem injection, hospitals look at manufacturing quality, vial sterility, consistent potency and reliable supply. Reso-Penem is produced at WHO-GMP compliant facilities under strict quality assurance and is distributed across India through the Resarcio network, so treatment protocols are not interrupted.

Clinical use

Reso-Penem biapenem 300mg injection is indicated in complicated urinary tract infections including pyelonephritis, intra-abdominal infections such as peritonitis and abdominal abscess, lower respiratory tract infections including hospital-acquired and broncho pneumonia, septicaemia, skin and soft tissue infections, gynaecological infections such as PID and endometritis, and severe systemic infections in hospitalised patients. Dosage and administration must be determined by the treating physician.